featured
Marijuana And Psychedelics Are ‘Best-Rated’ Drugs For Eating Disorder Symptoms, American Medical Association Study Finds

Published
2 weeks agoon

New research published by the American Medical Association (AMA) finds that marijuana and psychedelics “were among a small set of drugs” that showed promise for improving eating disorders. In fact, psychedelics and marijuana were “the highest rated” by participants in terms of effectively addressing their eating disorder symptoms.
“A striking outcome was the favorable self-reported ratings of psychedelics and cannabis for alleviating [eating disorder] symptoms,” authors wrote of their findings, “eclipsing the ratings of commonly prescribed psychotropics.”
The study, published in the Journal of the American Medical Association (JAMA) Network Open, evaluated a wide range of drugs and their subjective effects on eating disorders, including “caffeine, alcohol, nicotine, prescription psychotropics, psychedelics, ketamine, 3,4-methylenedioxymethamphetamine (or ecstasy) [MDMA], stimulants, opioids, and other drugs.”
Researchers looked at survey results from 6,612 people who answered questions about their past-year use of substances and they affected eating disorder (ED) and mental health symptoms.
“Cannabis and psychedelics were highest-rated for improving ED symptoms,” the report says, noting that prescription antidepressants “were rated highly for overall mental health but not for ED symptoms.”
Cannabis, psilocybin and LSD also “rated highly” in terms of overall improvement in mental health.
Alcohol, nicotine and tobacco, meanwhile, were rated by participants as “the most harmful drugs.”
Notably, only a small subset of substances appeared to make eating disorder symptoms better. Most made the symptoms worse.
“Cannabis and psychedelics were among a small set of drugs rated positively for relief of [eating disorder] symptoms.”
“When asked to identify their drug of choice for self-medicating ED symptoms, the most popular drug among respondents was cannabis,” the paper says. “When normalized by the number of users of that drug, the top drug was fluoxetine.”
The nine-author team behind the new study represents institutions including the University of Sydney and New South Wales Health, in Australia, as well as Kings College London in the U.K.
“The findings of this survey study of prescription and nonprescription drug use suggest that cannabis and psychedelics were perceived by survey respondents as efficacious in alleviating their ED symptoms,” authors wrote, “which supports further research in this area.”
“Overall, the best-rated drugs for ED symptoms among respondents were psilocybin, cannabis and lysergic acid diethylamide (LSD),” the paper says.
The team also observed that, “interestingly, MDMA and ketamine did not achieve the positive ratings evident with LSD and psilocybin, suggesting that classic psychedelics may possess unique properties in this regard.”
The new report notes that clinical trials are already underway into whether psilocybin is an effective treatment for one eating disorder, anorexia nervosa.
Authors noted that one way cannabis might help minimize symptoms in people with “food-aversive” eating disorders, including anorexia, is by “increasing the hedonic value of food.”
Separate federally funded research published last year explored exactly what happens in the brain after using marijuana that causes the “munchies”—findings authors of that study said could help lead to the development of targeted therapeutics for people with conditions such as anorexia and obesity.
Image element courtesy of Kristie Gianopulos.

Author: mscannabiz.com
MScannaBIZ for all you Mississippi Cannabis News and Information.
You may like
-
How AI Is Changing The Cannabis Industry
-
12 New York Cannabis Businesses Sue State Over School Proximity Fiasco
-
Massachusetts Auditor Notes ‘Violations’ and ‘Mismanagement’ At Cannabis Control Commission
-
Supreme Court Gives Marijuana Companies More Time To File Petition In Case Challenging Federal Prohibition
-
Canopy USA Appoints New Executive Team to Accelerate Growth
-
Washington Adult-Use Cannabis Sales Decline for Fifth Straight Year

AI is bringing changes and advancements to most industries – including cannabis
Whether you are a doctor in Nebraska, a restauranteur in Baltimore or senior engineer in Bellevue, Washington, it is upending how you do your job – both good and bad. Most areas of life are being touched and here is how AI is changing the cannabis industry. Artificial Intelligence (AI) is quietly reshaping nearly every corner of modern life, and the cannabis industry is no exception. From cultivation and retail to consumer transparency, AI is bringing new efficiency, accuracy, and trust to a market long been clouded by misinformation and stigma.
RELATED: Marijuana Might Be A Better Hurricane Party Guest
One of the most visible changes is how AI helps consumers track cannabis products. In an industry where strain names and effects can vary widely, AI-driven platforms are stepping in to provide clarity. Apps now use AI to analyze lab results, customer reviews, and even chemical profiles to match consumers with products best suited to their needs—whether it is better sleep, anxiety relief, or a more social buzz. Instead of relying on word-of-mouth or vague descriptions, consumers can access personalized recommendations grounded in hard data.
AI is also helping consumers find accurate, verifiable information in a marketplace which has sometimes struggled with exaggerated claims. Machine learning models can scan thousands of lab tests, regulatory filings, and scientific studies to identify trustworthy patterns. This gives guidance so customers are less likely to fall for marketing hype and more likely to discover which products are safe, effective, and compliant with state rules. For a generation used to researching everything from skincare ingredients to fitness supplements online, AI-driven cannabis insights are a welcome tool.
On the cultivation side, AI is revolutionizing how cannabis is grown. Smart sensors, combined with predictive algorithms, can monitor temperature, humidity, and light in real time. Farmers use these insights to maximize yield while minimizing water and energy use—an especially important consideration in an era of climate concerns and sustainability demands. By predicting plant health before problems arise, AI also reduces the need for pesticides and allows for more consistent harvests.
Retailers are benefiting as well. AI-powered inventory systems can predict which products will sell fastest, helping dispensaries avoid shortages or waste. Chatbots and virtual budtenders are guiding customers through product choices, mimicking the experience of a knowledgeable staff member but available 24/7 online. These digital assistants are especially appealing to Millennial and Gen Z consumers who prefer research-based shopping and minimal in-store pressure.
RELATED: Science Says Medical Marijuana Improves Quality Of Life
Looking ahead, AI could play a role in shaping cannabis policy and public health, too. By analyzing patterns in consumption data, researchers and regulators can better understand how cannabis affects communities, potentially leading to smarter regulations and safer use guidelines. In medical marijuana research, AI is proving especially powerful. Machine learning tools can process vast sets of patient data, clinical trial results, and genetic information to identify which cannabinoids or terpenes may be most effective for specific conditions such as chronic pain, epilepsy, or anxiety. This not only speeds up research but also helps doctors personalize treatment options for patients in ways not possible even a decade ago.
AI is doing more than making cannabis more high-tech—it’s making it more transparent, sustainable, and consumer-friendly. For an industry still overcoming decades of misinformation, which is a game-changing development.

Author: mscannabiz.com
MScannaBIZ for all you Mississippi Cannabis News and Information.
featured
12 New York Cannabis Businesses Sue State Over School Proximity Fiasco

Published
1 hour agoon
August 18, 2025
A dozen New York-licensed cannabis dispensaries are taking regulators to court over a screw-up by the state’s Office of Cannabis Management (OCM) related to their storefront locations being too close to schools.
The 12 petitioners filed the complaint on Aug. 15 in the New York Supreme Court in Albany County, against the OCM and the state’s Cannabis Control Board (CCB) over a school proximity correction that the office issued July 28. The correction, which impacts 108 dispensary licensees and 44 applicants with provisional licenses, intends to realign the OCM’s 500-foot measurement guidelines with state law.
Instead of continuing an entrance-to-entrance measurement between dispensaries and schools from the OCM’s erroneous 2022 guidance, the office now plans to measure the buffer zone from the entrance of a cannabis store in a straight line to the nearest property line boundary of a school’s grounds to move into compliance with New York’s cannabis law.
Following the proximity correction issuance, OCM Acting Executive Director Felicia A.B. Reid sent a letter on Aug. 6 to the 152 impacted businesses, clarifying that the 108 licensees may remain open or continue to work toward opening in their current locations as state officials push lawmakers for a legislative fix to grandfather in their locations. The 44 applicants, meanwhile, will need to move locations and will have access to $250,000 each from a $15 million relief fund to lessen their burdens.
Despite the assurance that the 108 licensees can remain put—and even continue to operate while the OCM delays reviewing any license renewals pending the legislative fix—the petitioners are asking the state Supreme Court in Albany to annul the OCM’s revised interpretation of Cannabis Law § 72(6) and declare that their locations remain compliant under a lawful reading of that law as well as the OCM’s 2022 guidance.
The 12 cannabis businesses are also asking that a State Supreme Court judge issue a preliminary and permanent injunction preventing the OCM from taking any enforcement actions against them based on the office’s new interpretation of the law, forcing the OCM to instead keep its previous interpretation that regulators used to review and approve site plans to issue licenses.
“Relying on those approvals, petitioners poured their life savings into launching their businesses,” the complaint states. “They signed leases, completed build-outs, hired employees and opened their doors to the public under the state’s very detailed framework. But now, in a complete about-face, OCM incredulously claims it got the law wrong all along.”
Furthermore, the petitioners claim that the OCM changed its guidance based on a new interpretation of the law without any formal rulemaking process or public notice. They argue that the informal rulemaking violates the State Administrative Procedure Act and that state officials arbitrarily redefined their own regulations.
Seven of the 12 businesses suing the state are either open or have received their final licensure to open, meaning the state has assured them they do not need to move locations and can remain open even with expired licenses—the OCM indicated it cannot approve their license renewals until state lawmakers act. However, some businesses fear that insurance companies and banks may refuse to service them if their licenses have expired, even in an interim phase.
“Petitioners face numerous collateral consequences as a result of OCM’s unlawful reinterpretation of Cannabis Law §72(6),” the complaint states. “Specifically, petitioners are required as part of their leases to be in compliance with all cannabis laws. OCM’s arbitrary and capricious actions have placed them at risk of falling into material breach with their lessors and, if allowed to continue, will cause them irreparable harm.”
These seven businesses include: ConBud (Manhattan), The Cannabis Place (Queens), Summit Canna (Bronx), Hush (Bronx), High Fade (Manhattan), Housing Works Cannabis Co. (Manhattan) and Common Courtesy Dispensary (Queens).
Meanwhile, the other five petitioners in the lawsuit are cannabis business applicants who received provisional licenses that are not yet finalized and will therefore be forced to pack up and change locations. These businesses include: Rezidue, Elise Pelka, Toastree, Monarch NYC and Luxe Leaf Boutique.
According to the lawsuit, while each of the five applicants has incurred significant buildout expenses, Rezidue, Elisa Pelka and Lux Leaf Boutique have completed their buildouts and were ready to begin operating upon a virtual inspection and gaining final licensure.
The petitioners’ construction costs ranged from $500,000 to $1,000,000, falling short of the $250,000 available per applicant in the state’s relief fund, according to the lawsuit.
“Petitioners have each expended nearly and in some cases over $1 million in preoperational expenses, and several million dollars each in post-operational expenses in reliance of OCM’s assurances,” the complaint states. “If OCM’s new and unlawful interpretation is allowed to remain in force, petitioners will also lose hundreds of thousands of dollars in deposits and lease termination penalties that cannot be recouped.
“Additionally, petitioners have all executed personal guarantees on their commercial leases, which would not only bankrupt the businesses, but also the individuals who guaranteed these leases.”
The petitioners argue that these expenses represent irreparable harm, which the court has the authority to prevent.
Other arguments the 12 cannabis businesses made in the lawsuit include:
- Retroactively revoking their license rights without notice or hearing violates due process;
- The OCM violated the equal protection clause of the state’s Constitution by revoking their proximity protections and thereby allowing competing applicants to gain favorable locations (in addition to the 500-foot school buffer zone, dispensaries must adhere to bigger buffer zones between other dispensaries).
- By pre-emptively denying licensees renewals, the OCM has engaged in unlawful “taking” without affording the petitioners due process of the law by way of a fair hearing;
- The plaintiffs’ investments have been rendered valueless by the OCM’s retroactive policy change, amounting to a “regulatory taking” under the New York Constitution; and
- The OCM’s new interpretation of the state’s cannabis law as it relates to school proximity requirements disproportionately harms those who were already disproportionately harmed by the drug war, which violates the state’s Marihuana Taxation and Regulation Act (MRTA) provisions to prioritize the inclusion, participation and sustainability of equity applicants.
“OCM’s reinterpreted rule disproportionately harms these stakeholders and licensees and undermines the very purpose of this law,” the complaint states about the latter bullet point. “Petitioners do not come from generational wealth and therefore cannot sustain such a hit. Their lives would be shattered while the OCM simply says ‘I’m sorry.’”
In particular, 11 of the plaintiffs are conditional adult-use retail dispensary (CAURD) licensees who were prioritized by the state because their businesses were owned by justice-involved individuals who reside in New York.
The 12th plaintiff is a social and economic equity (SEE) licensee, a category reserved for justice-involved individuals, minority- or women-owned businesses, distressed farmers, or service-disabled veteran-owned businesses.
“Petitioners would experience harm unlike anything they have faced before and would be relegated to levels of crippling debt, the likes of which they could never escape,” the complaint states. “The purpose of the MRTA was to undo these past injustices, not to exacerbate them.”

Author: mscannabiz.com
MScannaBIZ for all you Mississippi Cannabis News and Information.
featured
Massachusetts Auditor Notes ‘Violations’ and ‘Mismanagement’ At Cannabis Control Commission

Published
2 hours agoon
August 18, 2025
Massachusetts Auditor Diana DiZoglio last week released an audit of the state’s Cannabis Control Commission (CCC), claiming to have uncovered violations and mismanagement issues at the commission, NBC Boston reports.
The audit found that officials “failed to take appropriate steps and institute procedures” to guarantee the administering of cannabis industry license extensions, and that a “lack of supervision and minimal accountability over licensing staff members” helped contribute to the breakdown.
“CCC’s mismanagement of prorated fees for license extensions resulted in procedural inequity, revenue loss, and noncompliance with state regulations.” — Excerpt from the audit summary
The commission said it has “been working closely with the State Auditor’s Office for almost a year and will review the report released today in furtherance of our shared commitment to government improvement. Over the course of the audit period and since, the Commission has hired key leaders, made progress to address many of the issues referenced, and begun to move forward in a constructive way.”
The report was released hours after the commission voted unanimously to reinstate the license of Assured Testing, a testing lab accused of failing to report thousands of contaminated cannabis samples, the report said. The commission issued penalties against the lab, including a $300,000 fine and two years of probation. Additionally, the lab — which has publicly disagreed with the findings but says it will honor the commission’s terms for reinstatement — will have to hire an independent auditor, an internal control manager, and a new interim CEO.
“We are eager to return to what we do best: delivering scientific, evidence-backed testing with industry-leading cannabis expertise,” Assured Testing said in a statement.

Author: mscannabiz.com
MScannaBIZ for all you Mississippi Cannabis News and Information.

How AI Is Changing The Cannabis Industry

12 New York Cannabis Businesses Sue State Over School Proximity Fiasco

Massachusetts Auditor Notes ‘Violations’ and ‘Mismanagement’ At Cannabis Control Commission

Supreme Court Gives Marijuana Companies More Time To File Petition In Case Challenging Federal Prohibition

Canopy USA Appoints New Executive Team to Accelerate Growth

Washington Adult-Use Cannabis Sales Decline for Fifth Straight Year

Delaware Governor Seeks Marijuana Regulation Advice From Colorado Counterpart As State’s Legal Market Launches

Major trucking group’s cannabis rescheduling concerns (Newsletter: August 18, 2025)

From The Vault: The HIGH TIMES interview Allen Ginsberg (1992)

Court throws out part of New York’s marijuana licensing rules

Watch Immigration Enforcement Rattles the Cannabis Industry | SoCal Matters Season 2025

Two arrested as police close four unlicensed cannabis shops in Seneca Falls

High-potency cannabis use linked to psychosis | Watch News Videos Online

High Times Strains Of The Month: August 2025

Texas Crime Labs Say They Don’t Have Enough Resources To Test Hemp Products For THC As Lawmakers Consider Ban

Trump on changes to marijuana policy: 'We're looking at it'

Realtors’ Stolen Credit Cards Are Used to Build an Illegal Marijuana Farm

Grady County Sheriff's Office makes arrests in illegal marijuana bust

High Times Was The Most Influential Publication Of My Life

Revelry NYC 2025: Inside New York’s Cannabis Culture & Industry Festival

Revelry NYC 2025: Inside New York’s Cannabis Culture & Industry Festival

Indian Tribes See Opportunity In Hemp THC Products, Even In States That Continue Marijuana Criminalization

Two Oakland cannabis dispensaries targeted again by ram-raiding burglars

Trump on changes to marijuana policy: 'We're looking at it'

Alert: Department of Cannabis Control updates data dashboards with full data for 2023

Connecticut Appoints The US’s First Cannabis Ombudsperson – Yes there is a pun in there and I’m Sure Erin Kirk Is Going To Hear It More Than Once!

5 best CBD creams of 2024 by Leafly

EU initiative begins bid to open access to psychedelic therapies

New Study Analyzes the Effects of THCV, CBD on Weight Loss

Free delta-9 gummies from Bay Smokes

5 best autoflower seed banks of 2024 by Leafly

Discover New York’s dankest cannabis brands [September 2024]

Curaleaf Start Process Of Getting Their Claws Into The UK’s National Health System – With Former MP (Resigned Today 30/5/24) As The Front Man

May 2024 Leafly HighLight: Pink Runtz strain

Mississippi city official pleads guilty to selling fake CBD products

Press Release: CANNRA Calls for Farm Bill to Clarify Existing State Authority to Regulate Hemp Products

Local medical cannabis dispensary reacts to MSDH pulling Rapid Analytics License – WLBT

Horn Lake denies cannabis dispensary request to allow sale of drug paraphernalia and Sunday sales | News

5 best THC drinks of 2024 by Leafly

Nevada CCB to Accept Applications for Cannabis Establishments in White Pine County – “Only one cultivation and one production license will be awarded in White Pine County”

6 best CBD gummies of 2024 by Leafly

The Daily Hit: October 2, 2024

5 best delta-9 THC gummies of 2024 by Leafly

Weekly Update: Monday, May 13, 2024 including, New Guide for Renewals & May Board meeting application deadline

PRESS RELEASE : Justice Department Submits Proposed Regulation to Reschedule Marijuana

People In This State Googled ‘Medical Marijuana’ The Most, Study Shows

Thailand: Pro-cannabis advocates rally ahead of the government’s plan to recriminalize the plant

5 best THCA flower of 2024 by Leafly
Trending
-
California Cannabis Updates1 year ago
Alert: Department of Cannabis Control updates data dashboards with full data for 2023
-
Breaking News1 year ago
Connecticut Appoints The US’s First Cannabis Ombudsperson – Yes there is a pun in there and I’m Sure Erin Kirk Is Going To Hear It More Than Once!
-
best list1 year ago
5 best CBD creams of 2024 by Leafly
-
Business11 months ago
EU initiative begins bid to open access to psychedelic therapies
-
cbd1 year ago
New Study Analyzes the Effects of THCV, CBD on Weight Loss
-
Bay Smokes1 year ago
Free delta-9 gummies from Bay Smokes
-
autoflower seeds11 months ago
5 best autoflower seed banks of 2024 by Leafly
-
cannabis brands11 months ago
Discover New York’s dankest cannabis brands [September 2024]